Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM-24C5
- Development stage
- Phase 2
- Lead developer
- LaNova Medicines
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LM-24C5 is a bispecific monoclonal antibody designed to target both carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) on tumor cells and the costimulatory receptor 4-1BB (also known as CD137) on T cells. By binding simultaneously to CEACAM5 and 4-1BB, LM-24C5 redirects and activates T cells specifically at the site of CEACAM5-positive tumors, enhancing anti-tumor immune responses. This mechanism positions it as a novel immunotherapy for cancers expressing CEACAM5, such as colorectal cancer and other solid tumors. The drug is being developed by LaNova Medicines Limited and is currently in early-phase clinical trials for advanced solid tumors[3][7][8].
- Other names
- anti-CEA/anti-4-1BB bispecific antibody LM-24C5
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on LM-24C5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM-24C5.